Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial

Rhea-AI Summary

Therapeutic Solutions International (TSOI) has entered a $10 million Common Stock Purchase Agreement with GHS Investments, LLC. This agreement is structured as a non-toxic equity investment, providing funds to accelerate TSOI's Phase III clinical trial of JadiCells for COVID-19 related lung injury. The trial's success could lead to treatments for issues like 'long COVID.' TSOI holds 66 patents and has various INDs targeting conditions including Chronic Traumatic Encephalopathy and Acute Respiratory Distress Syndrome, demonstrating a robust focus on regenerative medicine and immunotherapy.

Positive

• Secured $10 million funding from GHS Investments to accelerate clinical trials.
• Phase III trial aims to assess efficacy of JadiCells for COVID-19 lung injury.
• Potential for expanding treatment into other pulmonary conditions, such as 'long COVID.'
• Possesses 66 filed and issued patents, indicating strong intellectual property portfolio.

Negative

• None.

Company Announces $10,000,000 Common Stock Purchase Agreement with GHS Investments, LLC.

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International (TSOI), a clinical stage regenerative medicine and immunotherapy company, announced today it has entered into an agreement with GHS Investments, LLC ("GHS") to purchase up to $10,000,000 of Registered Common Stock.

The agreement is on a look-back basis and there are no make-up provisions, a true non-toxic equity investment. GHS is a leading private investment and management group providing financial solutions for high potential small cap enterprises. GHS has made investments into multiple successful portfolio companies in the nano-market cap space that are seeking capital to measurably grow and scale their existing businesses to take advantage of emerging market sectors.

“This financing will allow the acceleration of our current Phase III clinical trial assessing efficacy of JadiCells, a novel adult stem cell, for treatment of COVID-19 associated lung injury,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International. “The implications of this trial are far-reaching in that success will open the door for entry into other pulmonary indications including ‘long COVID’ which remains a significant health problem.”

Therapeutic Solutions International has 66 filed and issued patents, multiple IND’s covering Chronic Traumatic Encephalopathy (CTE), Acute Respiratory Distress Syndrome (ARDS), Chronic Obstructive Pulmonary Disease (COPD), and solid tumor Cancer’s as well as numerous preclinical and pilot clinical data around immunotherapy, oncology, and stem cell therapeutics.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005776/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What is the purpose of the $10 million agreement with GHS Investments for TSOI?

The agreement aims to fund TSOI's Phase III clinical trial assessing JadiCells for treating COVID-19 associated lung injury.

How could the Phase III trial impact TSOI's business operations?

Success in the trial could open avenues for TSOI to address other pulmonary conditions, potentially expanding its market reach.

What are JadiCells and their significance in the trial?

JadiCells are a novel adult stem cell therapy being tested for their efficacy in treating lung injuries caused by COVID-19.

How many patents does TSOI currently hold?

Therapeutic Solutions International holds 66 filed and issued patents across various medical conditions.